Patient preference
Patients who completed both IV and oral dosing were asked which
treatment they preferred after completion of both treatment periods.
Thirty (75%) subjects preferred oPac+E treatment over IV paclitaxel,
while IV paclitaxel was preferred over oPac+E in 6 (15%) subjects. No
treatment preference was reported in the remaining 4 subjects.